40 results about "Dengue vaccine" patented technology

The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.

The invention provides tetravalent Dengue vaccines, and methods of using these vaccines to prevent or to treat Dengue infection.

The invention provides a Japanese encephalitis/dengue chimeric virus, which is obtained by replacing a prM/E gene in Japanese encephalitis cDNA clone with the prM/E gene of dengue virus type II. IFA and Western blot confirm that the chimeric virus can express E protein of a dengue virus and can stabilize passage in C6/36 cells. The invention lays a foundation for developing a dengue virus vaccine. The chimeric virus can be taken as a vaccine to immunize animals so as to enable the animals to obtain immune protection against the dengue virus.

The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.

The present invention is related to a biodegradable high-efficiency dengue vaccine, a method for making the same, and a pharmaceutical composition comprising the same. The biodegradable high-efficiency dengue vaccine comprises a biodegradable nanocomplex with electric properties holding a dengue viral protein inside. An organism has antibody responses after vaccination with the biodegradable nanocomplex twice. Accordingly, in comparison with the Alum adjuvant and Ribi adjuvant used in the traditional dengue vaccine of the prior art, the vaccination times in the present invention is decreased to further reduce the vaccination cost, so the biodegradable high-efficiency dengue vaccine is good for being a commercial vaccine.

The present invention relates to a dengue vaccine, a pharmaceutical composition including the same, and a nucleotide sequence. The dengue vaccine includes N and C termini-deleted nonstructural protein ΔNC NS1 with a peptide fragment from amino acids 36 to 270, which is derived from dengue virus nonstructural protein 1 (DV NS1) with deletions of N-terminal region from amino acids 1 to 35 and C-terminal region from amino acids 271 to 352. The dengue vaccine of the present invention is depleted of cross-reactivity with endothelial cells and platelets, and can shorten the bleeding time.

The present invention provides compositions directed to recombinant flavivirus E glycoprotein ectodomain dimers for use in diagnostic and immunotherapeutic methods.

The invention discloses a method for evaluating the immune effect of a dengue vaccine. The method comprises the steps of carrying out toxicity attack on a newly born offspring suckling mouse of an immunized adult Balb/c mouse in an encephalic injection manner by virtue of the dengue virus, and observing and recording the death condition of the suckling mouse within 21 days after the toxicity attack so as to evaluate the immune effect of the vaccine. Compared with an existing method for evaluating the immune effect of the dengue vaccine by virtue of a wild suckling mouse model or a mouse modelwith immunologic function defects, the method has the advantages that the disadvantages of the two models are avoided, and the constructed method can be used for accurately evaluating the immune effect of the vaccine in an actual user object and is relatively economic, practical, simple and feasible.

The present invention relates to a yellow fever (YF) vaccine for use in a method for inducing a protective immune response against yellow fever, wherein said method comprises concomitantly administering said yellow fever vaccine to a human subject together with a tetravalent dengue vaccine which comprises a live attenuated dengue virus of each of serotypes 1 to 4. This invention also pertains to a tetravalent dengue vaccine which comprises a live attenuated dengue virus of each of serotypes 1 to 4 for use in a method of inducing a protective immune response against yellow fever, wherein said method comprises concomitantly administering said tetravalent dengue vaccine to a human subject together with a yellow fever (YF) vaccine.

The present invention relates to an attenuated dengue virus vaccine. In present invention, target mutagenesis at Glu₃₄₅Lys was constructed in two infectious cDNA clones of a recombinant version of wild type virus DEN-4 2A and its derived 3′ NCR deletion mutant vaccine candidate virus DEN-4 2AΔ30. Using PCR-mediated site-directed mutagenesis method, the infectious cDNA clone-derived Glu_345-Lys mutants of DEN-4 2A and DEN-4 2AΔ30 were passaged in Vero cells and MRC-5 cells for five consecutive times. The results shows that single point mutation E-Glu₃₄₅Lys of DEN-4 2A and DEN-4 2AΔ30 were found stably existed when passaged in MRC-5 cells, which means mutagenesis at Glu₃₄₅Lys of DEN-4 2A and DEN-4 2AΔ30 are both suitable to be probagated in MRC-5 cell for producing virulence attenuated dengue virus vaccine.

The invention provides a dengue virus vaccine. The invention starts from the currently rarely reported T-cell immunity of the dengue virus, a simian adenovirus carrier is used to construct the vaccineto break through the limitations of the human adenovirus carrier in the practical application, an Ad carrier vaccine C9-NS1 for the dengue virus II is successfully constructed, the carrier clones a PCR (Polymerase Chain Reaction) product rapidly through the clone technology, the double enzyme digestion operations of a plasmid and a target fragment are avoided, and the carrier is relatively convenient and efficient. A histidine tag is arranged at the end C, expressing the fusion protein, of the carrier, so that the affinity chromatography and purification of the recombinant protein is facilitated, and the protein of the histidine tag is relatively small and barely produces effects on the activity and the function of the expression protein. The immunologic function of the vaccine from the protein NS 1 of the dengue virus is evaluated comprehensively from multiple aspects, and a foundation is laid for the further research and development of the efficient spectrum dengue gene vaccine.